Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder

Part of paid clinical trials in Belmont, Massachusetts.

Sponsor
Mclean Hospital
Study ID
NCT05457465
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Cannabidiol — DRUG
    Custom formulation of a hemp-derived, high-CBD product that contains no THC.

Study Details

Preliminary data have suggested that cannabidiol (CBD) may have a number of clinical benefits, including anti-anxiety and antidepressant properties. This study is a pilot open-label clinical trial assessing a custom-formulated high-CBD product over the course of 4 weeks in patients with bipolar disorder who experience anxiety.

Key Dates

Start date
Jun 1, 2023
Status verified
Mar 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Hemp-Derived Cannabidiol Solution
    Patients will administer a custom-formulated, hemp-derived, high-CBD solution twice daily for 4 weeks

Primary Outcome Measure

Change in self-reported ratings of anxiety on the Beck Anxiety Inventory (BAI) [ Time Frame: 4 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
McLean HospitalBelmontMassachusetts02478
Rosemary Smith, B.S.
[email protected]
617-855-3338

Find similar trials in Belmont, MA

By condition
Bipolar disorder
By specialty
PsychiatryMental healthBehavioral health
By research site
McLean Hospital· Belmont, MA

Related Studies